Antares Pharma

Antares Pharma is a revenue-generating product-focused specialty pharmaceutical company that has developed three proprietary platforms, two of which now include FDA-approved products. Its products typically improve safety and efficacy profiles by minimizing dosing and reducing side effects while improving patient compliance. It focuses on self-injection pharmaceutical products and technologies and topical gel-based products. Its subcutaneous injection technology platforms include Vibex disposable pressure-assisted auto-injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Since the approval of Clarus' TRT drug Jatenzo on March 28, Antares shares have been under pressure, breaking an upward trend to the downside.

Antares Pharma: What The Market Is Missing

Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q1 2019 Results - Earnings Call Transcript

Regardless of the company’s growing, diversified portfolio and pipeline of drugs, Antares stock continues to trade like it is a one-product company.

Antares Pharma: It's The Business Model Stupid

News for Antares Pharma Stock (ATRS)